Use of Continuous Positive Airway Pressure Ventilation as a Support During Coronary Angioplasty in Patients with Acute Myocardial Infarction: Safety and Feasibility

急性心肌梗死患者冠状动脉成形术中应用持续气道正压通气支持:安全性和可行性

阅读:1

Abstract

Background/Objectives: To evaluate the safety and feasibility of continuous positive airway pressure (CPAP) in patients with acute myocardial infarction (AMI) and acute decompensated heart failure (ADHF) during percutaneous coronary intervention (PCI). Non-invasive ventilation (NIV) is an established treatment for ADHF. Methods: All consecutive patients admitted to Santa Croce Hospital of Cuneo, receiving CPAP for ADHF in the cath lab during PCI for AMI, were included in a case series. Results: Between December 2018 and March 2021, 25 pts were included (median age 78 yrs, 48% female), with 64% of patients presenting with ST-elevation AMI and 17 (69%) in cardiogenic shock. At admission median left ventricular ejection fraction was 35 (20-60)% and eight (32%) patients had severe mitral regurgitation. Median PaO(2)/FiO(2) was 183 (141-261) mmHg/%, lactate level 2.4 (1.3-3.8) mmol/L, and NTproBNP 7882 (3139-35,000) ng/L. CPAP was positioned and managed by nurses in all cases. Median FiO(2) was 50 (35-100)% and median positive end-expiratory pressure was 7.5 (5-12) cmH(2)O. CPAP was generally well tolerated in 22 (88%) patients. One patient suffered cardiac arrest that led to CPAP interruption due to resuscitation maneuvers. No patient required orotracheal intubation in the cath lab. The post-procedural PaO(2)/FiO(2) ratio substantially improved to 230 (175-356) mmHg/% (p = 0.007) and lactate decreased to 1.5 (1.0-1) mmol/L (p = 0.002). One patient died during hospital stay due to underlying disease, unrelated to the study procedure. Conclusions: CPAP during PCI in patients with AMI and ADHF seems feasible, safe, and well tolerated. Larger studies are warranted to confirm these results.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。